Congenital toxoplasmosis: Scientific Background, Clinical Management and Control

Front Matter....Pages i-xi
Congenital toxoplasmosis: past, present and future....Pages 1-7
Biology of Toxoplasma gondii ....Pages 9-25
Placenta physiology....Pages 27-35
Basic immunology: the fetus and the newborn....Pages 37-68
The immunology of Toxoplasma gondii infection in the immune-competent host....Pages 69-82
Biological diagnosis of congenital toxoplasmosis: methods....Pages 83-94
Drugs effective against Toxoplasma gondii . Present status and future perspective....Pages 95-110
Clinical aspects of infection during pregnancy....Pages 111-120
Diagnosis in the pregnant woman....Pages 121-130
Laboratory diagnosis of fetal toxoplasmosis....Pages 131-139
Effect of treatment of the infected pregnant woman and her foetus....Pages 141-152
Clinical picture. Neonatal signs and symptoms....Pages 153-164
Ophthalmology in the neonate with congenital toxoplasmosis....Pages 165-177
Biological post-natal diagnosis of congenital toxoplasmosis....Pages 179-188
Management of and outcome for the newborn infant with congenital toxoplasmosis....Pages 189-213
Recurrent ocular disease in congenital toxoplasmosis: clinical manifestations....Pages 215-229
Laboratory diagnosis of ocular toxoplasmosis: serological and PCR based analysis of ocular fluids....Pages 231-235
Epidemiology of infection in pregnant women....Pages 237-249
Epidemiology of ocular Toxoplasma ....Pages 251-259
Veterinary aspects of Toxoplasma infection....Pages 261-269
The scientific basis for prevention of Toxoplasma gondii infection: studies on tissue cyst survival, risk factors and hygiene measures....Pages 271-275
Prevention of congenital toxoplasmosis in Austria: experience of 25 years....Pages 277-292
Prenatal screening and prevention of congenital toxoplasmosis in France....Pages 293-298
What informations should be extracted from the national programs for the prevention of congenital toxoplasmosis in Austria and in France?....Pages 299-303
Neonatal screening for congenital infection with Toxoplasma gondii ....Pages 305-311
Strategies for development of vaccines against Toxoplasma gondii ....Pages 313-322
Conclusion....Pages 323-324